Profile data is unavailable for this security.
About the company
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
- Revenue in USD (TTM)57.37bn
- Net income in USD4.16bn
- Incorporated2012
- Employees55.00k
- LocationAbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
- Websitehttps://www.abbvie.com/
Mergers & acquisitions
| Acquired company | ABBV:NYQ since announced | Transaction value |
|---|---|---|
| Capstan Therapeutics Inc | 3.81% | 2.10bn |
| Merck KGaA-Biologics Plant | 10.32% | -- |
| Nimble Therapeutics Inc | 9.28% | 200.00m |
| Aliada Therapeutics Inc | 0.75% | 1.40bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co Inc | 63.92bn | 17.43bn | 204.70bn | 75.00k | 11.87 | 4.24 | 9.26 | 3.20 | 6.87 | 6.87 | 25.19 | 19.21 | 0.5786 | 2.31 | 5.77 | 852,293.30 | 15.79 | 9.52 | 20.46 | 12.64 | 77.07 | 73.47 | 27.30 | 17.87 | 1.16 | 23.90 | 0.4186 | 72.96 | 6.74 | 10.40 | 4,589.59 | 24.64 | -0.5885 | 6.66 |
| AbbVie Inc | 57.37bn | 4.16bn | 338.09bn | 55.00k | 81.61 | 238.08 | 26.81 | 5.89 | 2.35 | 2.35 | 32.39 | 0.804 | 0.4025 | 3.83 | 4.70 | 1,043,036.00 | 2.95 | 5.44 | 4.06 | 7.09 | 70.69 | 68.89 | 7.33 | 13.73 | 0.6359 | 7.80 | 0.9795 | 134.96 | 3.71 | 11.11 | -12.07 | -11.58 | 12.03 | 7.69 |
| Johnson & Johnson | 90.63bn | 22.66bn | 392.14bn | 138.10k | 17.43 | -- | 17.32 | 4.33 | 9.35 | 9.35 | 37.37 | -- | -- | -- | -- | 656,241.90 | -- | 8.63 | -- | 11.73 | 67.98 | 68.70 | 25.00 | 18.29 | -- | -- | -- | 74.74 | 4.30 | 1.60 | 5.55 | -1.43 | 4.81 | 5.54 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2025 | 177.27m | 10.04% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 91.03m | 5.16% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 79.96m | 4.53% |
| Geode Capital Management LLCas of 31 Mar 2025 | 38.25m | 2.17% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 34.98m | 1.98% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 33.51m | 1.90% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2025 | 25.27m | 1.43% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 25.10m | 1.42% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2025 | 23.25m | 1.32% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2025 | 20.54m | 1.16% |
